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TCT-122
Electrode irrigation alters RF ablation treatment zone geometry and preserves
medial and adventitial tissue while maintaining injury to renal nerves
John Keating1, Peter Markham2, James Stanley1, Abraham R. Tzafriri2, Gee Wong1,
Anna Spognardi1, Kristine Fuimaono3, Debby Grunewald3, Patrick O'Fallon3,
Elazer Edelman4
1CBSET, Inc., Lexington, MA, 2CBSET Inc., Lexington, MA, 3Cordis/Biosense
Webster, Inc. a Johnson & Johnson Company, Irwindale, CA, 4Harvard-MIT
Biomedical Engineering Center, Cambridge, Massachusetts
Background: We quantitatively compared lesion geometry and artery and nerve
injury with and without irrigation during RF ablation to enable optimization of
catheter design and understanding of temperature gradients.
Methods: RF ablations, using spatially discrete electrodes, were conducted in swine
using THERMOCOOL irrigated tip catheter (Biosense Webster, CA) with and
without irrigation. Arteries were harvested at 7d and serial sectioned every 300 mm
and quantiﬁed histomorphometrically (Fig 1).Results: Surface irrigation lowered affected luminal circumference (irrigated 6.1% vs.
non-irrigated 44.6%); media (irrigated 11.7% vs. non-irrigated 35.4%); and EEL
circumference (irrigated 18.9% vs. non-irrigated 45.4%). RF ablation effects in the
nerve-rich adventitia were less sensitive to irrigation: width (irrigated 3.8mm vs. non-
irrigated 4.8mm) and depth (irrigated 5.1mm vs. non-irrigated 3.4mm). Morphologic
nerve changes within the ablation zones were comparable with and without irrigation
and were considered to be marked and necrotic/degenerative.
Conclusions: Irrigation preserved arterial integrity and reduced linear, circumferential,
and radial injury at the luminal surface and within media and adventitia while providing
comparable nerve injury. These data were used to develop a computational model of RF
energy delivery and injury for further optimization of irrigation and powering protocols.
TCT-123
Preliminary safety and efﬁcacy results from the REALISE trial: REnAL
denervatIon by ultraSound transcatheter Emission
Gilles Montalescot1, Philippe Cluzel1, Atul Pathak2, Hervé Rousseau2,
Jérôme Roncalli2, Meyer Elbaz2, Ghalia Anzaha1, Vincent Cabane3, Mano Iyer4,
Xavier Girerd1
1Pitié-Salpêtrière University Hospital, Paris, France, 2Rangueil University Hospital,
Toulouse, France, 3ReCor Medical, Paris, France, 4ReCor Medical, Menlo Park, CA
Background: Catheter-based renal denervation has emerged as a method for treating
the overactivity of the sympathetic nervous system. The PARADISE system (ReCor
Medical, Menlo Park, CA) is a unique therapeutic non-focused ultrasound system
designed to perform circumferential renal denervation while preventing damage to the
renal artery. The purpose of the REALISE trial is to evaluate the safety and efﬁcacy of
the PARADISE system in patients suffering from resistant hypertension.
Methods: The REALISE trial is a 20-patient prospective study conducted by multi-
disciplinary teams at two sites in France (Hôpital Pitié-Salpêtrière, Paris; Hôpital
Rangueil, Toulouse). Patients suffering from resistant hypertension as deﬁned by the
ESH-ESC guidelines (ofﬁce blood pressure above 140/90 mmHg with a minimum of
3 antihypertensive drugs including a diuretic) were screened and eligibility further
conﬁrmed by home and/or ambulatory measurements. Renal denervation was per-
formed bilaterally with the PARADISE system, delivering 2 to 3 ultrasound emissionsB40 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jin each artery. All patients underwent CT-scan or MRI at baseline and follow-up to
assess the renal arteries.
Results: Preliminary results indicated that 63% of enrolled and treated patients were
under spironolactone therapy. Bilateral denervation was performed by delivering an
average of 5.7 ultrasound emissions in each subject (average heating time 3.3 minutes
per subject). Sedatives and analgesics were administered during the intervention and
the treatment was well tolerated by all patients. Preliminary results at 6 months were
comparable to published data on radiofrequency renal denervation with an average
reduction in ofﬁce and ambulatory blood pressure of -21/-9 mmHg and 9/ 4 mmHg,
respectively. Systematic imaging of the renal arteries showed no arterial stenosis or
arterial damage at follow-up.
Conclusions: Endovascular ultrasound renal denervation appears to be a safe and
effective treatment for resistant hypertension. Results on all 20 patients from the
REALISE study will be presented at the conference.
TCT-124
A novel appliance for transcatheter mitral cerclage annuloplasty
June-Hong Kim1, Si Chan Sung1, Jongha Park1, Jeong Heo2, Yong-Hyun Park1,
Jin-Pyong Kim3, Jun-Ho Kim1, Robert J. Lederman4
1Pusan National University Yangsan Hospital, Yangsan, 2Pusan National University
Hospital, Busan, 3Koswire RND center, Busan, 4NIH
Background: Mitral cerclage annuloplasty is a transcatheter coronary sinus annulo-
plasty that establishes circumferential tension around the mitral annulus by traversing
the basal interventricular septum between the great cardiac vein and the right
ventricular outﬂow tract. We have developed a novel implant to effect annuloplasty
while preventing myocardial erosion; avoiding compression of coronary arteries,
tricuspid leaﬂet, AV node; and displaceing the knot ﬁxation to a safe caval location.
Methods: The cerclage appliance is positioned over a 0.018" nylon-coated ﬂexible
and radiopaque stainless steel braidwire. It consists of conjoined semirigid coronary
sinus and trans-tricuspid limbs (CS, TV, Figure) and is used along with a coronary
artery protection arch. X-ray guided cerclage was performed in swine (n¼6,
55w80kg) to investigate the device performance.
Results: The cerclage appliance was easily delivered over the cerclage suture and
assumed its intended anatomic position along the coronary sinus and across the
tricuspid valve. Tension accomplished circumferential mitral annular reduction while
the TV limb protected the TV and AV node from direct contact. Neither conduction
block nor TV malfunction was observed after two-week survival (n¼1).
Conclusions: This novel cerclage appliance addresses potential shortcomings of
transcatheter cerclage annuloplasty in a simple-to-deploy device.TCT-125
Novel Thoracoscopically Assisted Trans-Catheter Ventricular Restoration
Therapy: Feasibility and Efﬁcacy in an Anteroseptal Aneurysmal Ovine Model
Yanping Cheng1, Geng-Hua Yi1, Lon S. Annest2, Kevin Van Bladel2,
Masahiko Shibuya1, Carlos A. Gongora1, Gerard B. Conditt1, Armando Tellez1,
David Schickling2, Andrew Boyle3, Ryan A. Brown4, Vasco G. Ribeiro5,
Greg L. Kaluza1, Juan Granada1
1Cardiovascular Research Foundation, Orangeburg, NY, 2BioVentrix, San Ramon,
CA, 3UCSF, San Francisco, CA, 4John Muir Medical Center, Concord, CA, 5Vila
Nova De Gaia Hospital Center, Porto, Portugal
Background: Surgical ventricular reconstruction has been used as heart failure
treatment in patients with large ventricular aneurysms. Based on a well-established
device-based (BioVentrix, San Ramon, CA) surgical technique operation, this study
assessed the feasibility of performing minimally invasive thoracoscopically assisted
transcatheter ventricular restoration (TCVR) in an anteroseptal ovine infarction model.
Methods: Ventricular aneurysmal model development was achieved by coil-occlusion
of the left anterior descending artery. 8 weeks after occlusion, TCVR was performed
in ﬁve sheep via a 4 cm left thoracotomy. Under endoscopic and ﬂuoroscopic guid-
ance, LV scar was visualized and trans-epicardial puncture was performed advancing
a guidewire at the lateral margin of the scar, across a portion of the LV, and through
the interventricular septum into the right ventricle. With one end still protruding from
the left chest, the guidewire was retrieved with a snare via the right external jugular
vein through a percutaneous approach. Then an inner anchor on a tether was inserted
over the wire and positioned on the right side of the interventricular septum. The
opposite end of the tether protruded through LV anterolateral wall and an outer
locking anchor was deployed over the tether on the LV anterior epicardium. Serial
pairs of anchors were then approximated to exclude the intervening portion of theTCT Abstracts/ORAL/First-in-Human Studies: Global Regulatory and Translational Considerations
www.jacctctabstracts2013.com MONDAY, OCTOBER 28, 2013, 8:00 AM–6:35 PMwall. LV performance was evaluated before (baseline) and immediately after device
implantation by echo.
Results: TCVR was successfully performed in all the animals. Immediately after the
procedure and compared to baseline, LV end-systolic volume was decreased by 54%
(26.98.7 vs. baseline 60.122.2ml, p<0.01) and end-diastolic volume decreased by
34% (54.511.0 vs. baseline 85.620.6ml, p<0.05). Ejection fraction was signiﬁ-
cantly increased by 19.8% (519% vs. baseline 319%, p<0.001) and stroke volume
was preserved (27.56.9 vs. baseline 25.53.8ml, p¼NS).
Conclusions: Minimally invasive thoracoscopically assisted TCVR is feasible and
resulted in signiﬁcant improvement in cardiac volume and ejection fraction in an ovine
infarction model.
TCT-126
First-in-human experience with a novel high-ﬂow percutaneous heart pump
David Kandzari1, Adrian Ebner2, Paul Muller3
1Piedmont Heart Institute, Atlanta, GA, 2Italian Hospital, Asuncion, Paraguay,
3Thoratec Corporation, Pleasanton, CA
Background: High-risk percutaneous coronary interventions (HRPCI) involving
complex disease and/or depressed cardiac function have become increasingly
common. The potential beneﬁt from short-term mechanical circulatory support is
suggested by observations that intraprocedural hemodynamic compromise may impact
completeness of revascularization and contribute to adverse events. We report
outcomes from a First in Human trial using the HeartMate PHP (Percutaneous Heart
Pump) in patients undergoing HRPCI.PHP is a catheter-based axial ﬂow pump
designed to provide partial left ventricular support of up to 5 lpm and is rapidly
delivered percutaneously via typical femoral insertion. The 12F catheter contains
a distal collapsible covered nitinol cannula with an integrated impeller that expands to
24F when deployed across the aortic valve.
Methods: 10 patients with complex coronary disease and reduced LV function (EF from
26% - 34% prior to PCI) underwent elective HRPCI while on PHP support. Device
success, deﬁned as the deployment, use and removal of PHP without device failure; and
periprocedural measures of hemodynamics and cardiac performance were evaluated.
Major adverse safety and efﬁcacy events were assessed during PHP use and at 30 days.
Results: Among the ﬁrst 3 patients, PHP was successfully deployed in all patients
without complications. There was no periprocedural or follow-up echocardiographic
evidence of aortic regurgitation or valve abnormalities. All patients remained hemo-
dynamically stable while on support and all planned target lesions were revascular-
ized. The PHP was successfully removed in all cases and there were no adverse patient
events while on device support through 30 days. (Outcomes on the full patient series
will be presented when complete.)CARDIAC INDEX MAP PCWP
Baseline
On
Support Baseline
On
Support Baseline
On
Support
Pt #1 2.8 3.17 73 65 41 16
Pt #2 2.67 2.45 84 112 11 5
Pt #3 2.3 3.26 97 119 8 9Conclusions: In a First in Human trial involving patients undergoing HRPCI,
hemodynamic support using the HeartMate PHP is feasible and safe.O
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TCT-127
Trans-Auricular Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA)
Toby Rogers1, Kanishka Ratnayaka1, William H. Schenke1, Anthony Z. Faranesh1,
Merdim Sonmez1, Dominique N. Franson1, Robert J. Lederman1
1National Heart Lung and Blood Institute, National Institutes of Health, Bethesda,
MD
Background: Functional tricuspid regurgitation (TR) is clinically signiﬁcant. TR
predicts mortality independent of LVEF, age or pulmonary artery pressure. PersistentJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 Years oTR after mitral valve surgery is an independent poor prognostic sign. Tricuspid valve
repair is usually an adjunct to other surgery. We present TRAIPTA, a novel percu-
taneous treatment of functional TR. We demonstrate pre-clinical feasibility in swine.
Methods: Through the femoral vein and under X-ray guidance, the pericardial space
is accessed by puncture through the right atrial appendage (Panel A). A custom
memory-shape delivery device positions a suture circumferentially in the AV groove
(Panel B) and used to deploy a semi-rigid device to apply direct compression to the
tricuspid annulus. The suture is tightened to achieve the desired degree of annulo-
plasty (Panel C), then secured and cut. The atrial appendage access is closed with an
occluder.Results: In naïve swine, trans-auricular pericardial access was easy and safe. The
TRAIPTA device is consistently delivered to the AV groove, tension can be selec-
tively applied to the tricuspid annulus, and RV geometry interactively altered.
Conclusions: Percutaneous treatment of functional TR is feasible in swine using
TRAIPTA.
TCT-128
Transcatheter Implantation of Self-Expandable Vena Cava Valves for Treatment
of Tricuspid Regurgitation: First-Human-Case Description
Hans R. Figulla1, Torsten Doenst2, Marcus Franz2, Ali Hamadanchi3,
Daniel Kretzschmar3, Alexander Lauten2
1Friedrich-Schiller Universitat, Jena, Germany, 2University Hospital Jena, Jena,
Germany, 3Heart Center of the Friedrich-Schiller-University, Jena, Thuringia
Background: Despite the recent advances in interventional treatment of heart valve
disease, no transcatheter approach is established for severe tricuspid regurgitation
(TR). Single valve implantation into the inferior vena cava (IVC) has been suggested,
which however only partially resolves the hemodynamic sequelae of TR. After
extensive preclinical evaluation, we herein report the ﬁrst human case of bi-caval self-
expanding valve implantation (CAVI) in the superior (SVC) and inferior vena cava.
Methods: CAVI was performed in a 83-year-old patient with severe TR, chronic right
heart failure and congestive hepatopathy. Two self-expanding pericardial valves were
custom-made to ﬁt to the anticipated implantation zones in the caval veins of this
patient. Both devices were implanted under ﬂouroscopy using a 27F-catheter and
deployed at the level of the cavo-atrial junction of the SVC and the IVC. To protect
the hepatic veins from backward ﬂow, the inferior valve was aligned just above the
hepatic vein inﬂow and deployed with the valve protruding into the right atrium (RA).
Results: After deployment and during 3-month follow-up excellent valve function
was observed. The procedure resulted in a marked reduction of the pressure in the
SVC and IVC from 27/14mmHg and 28/15mmHg to 21/7mmHg and 13/6mmHg at 3
month, respectively. After implantation symptoms of right heart failure resolved and
did not recurr during follow-up and synthetic liver function recovered. The patients
physical capacity improved with an increase in distance covered in 6-minute-walk-test
from 20m before implantation to 200m at 3 month.
Conclusions: In this ﬁrst-in-man experience, transcatheter CAVI proved feasible and
resulted in persistent hemodynamic and clinical improvement. Further conﬁrmatory
experience with longer follow-up is required to evaluate the clinical beneﬁt of the
procedure.
TCT-129
Percutaneous Transfemoral Management of Severe Secondary Tricuspid
Regurgitation with Edwards Sapien XT Bioprosthesis in patients with severe
heart failure: ﬁrst in man experience
Michael Laule1, Gert Baumann2, Fabian Knebel2, Wasiem Sanad2, Verena Stangl3,
Karl Stangl4
1Charité University Hospital, berlin, Berlin, 2Charite, Berlin, Berlin, 3Charité, Berlin,
Berlin, 4Charité - Campus Mitte, Berlin, Germany
Background: Severe tricuspid regurgitation (STR) is a common ﬁnal pathway in
advanced stages of heart failure (HF) and associated with increased morbidity and
mortality. The prevalence of moderate to severe TR is 35% in HF patients occurring in
1.6 Mio patients in the US. In advanced TR stages, the surgical risk is prohibitively
high, alternative approaches are therefore required. Here we describe the feasibility as
well as periprocedural and short-term outcomes of a novel ﬁrst-in-man single caval
and dual caval approach for implantation of the Edwards Sapien XT.
Methods: Vena cava inferior (VCI) single valve approach: to guarantee stable
placement we prepared a landing zone by implanting a self-expanding 30/60-mm
Sinus XL Stent in the IVC segment downstream of the RA. To further downsize thef Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013 B41
